Luftner, D; Bartsch, R; Breitenstein, U; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Schwitter, M; Zaman, K; Wrobel, D; Guth, D; Terhaag, J; Zaiss, M; Distelrath, A; Lorenz, A; Schinkothe, T; Harbeck, N.
Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ONCOL RES TREAT. 2022; 45(SUPPL 3): 20-21.
[Poster]
Web of Science